{"id":31282,"date":"2025-04-07T15:48:58","date_gmt":"2025-04-07T07:48:58","guid":{"rendered":"https:\/\/flcube.com\/?p=31282"},"modified":"2025-04-07T15:48:59","modified_gmt":"2025-04-07T07:48:59","slug":"abl-bio-and-gsk-partner-on-neurodegenerative-disease-therapies-with-grabody-b-platform","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=31282","title":{"rendered":"ABL Bio and GSK Partner on Neurodegenerative Disease Therapies with Grabody-B Platform"},"content":{"rendered":"\n

South Korea-based clinical-stage biotech ABL Bio Inc. (KOSDAQ: 298380<\/a>) has entered into a licensing agreement with GlaxoSmithKline (GSK, NYSE: GSK<\/a>). The collaboration grants GSK access to ABL Bio’s Grabody-B blood-brain barrier (BBB) shuttle platform to develop novel medicines for neurodegenerative diseases. The deal encompasses multiple programs across therapeutic modalities, including antibodies, polynucleotides, and oligonucleotides such as siRNA and ASOs.<\/p>\n\n\n\n

Agreement Details<\/strong>
Under the terms of the agreement, GSK will pay ABL Bio up to GBP 77.1 million (USD 99.6 million) in upfront and near-term payments, including an immediate upfront payment of GBP 38.5 million (USD 49.7 million). Additional payments could reach up to GBP 2.075 billion (USD 2.68 billion) for research, development, regulatory, and commercialization milestones, alongside tiered royalties on net sales.<\/p>\n\n\n\n

Technology Transfer and Development<\/strong>
GSK will assume responsibility for preclinical and clinical development, manufacturing, and commercialization of products derived from the Grabody-B platform. This technology enables the efficient delivery of therapeutic agents across the blood-brain barrier, a critical advancement for treating neurodegenerative conditions.-Fineline Info & Tech<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"

South Korea-based clinical-stage biotech ABL Bio Inc. (KOSDAQ: 298380) has entered into a licensing agreement…<\/p>\n","protected":false},"author":1,"featured_media":31284,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[7,10],"tags":[1315,278,184,1314,914],"class_list":["post-31282","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-company","category-deals","tag-abl-bio","tag-glaxosmithkline","tag-gsk","tag-kosdaq-298380","tag-nyse-gsk"],"yoast_head":"\nABL Bio and GSK Partner on Neurodegenerative Disease Therapies with Grabody-B Platform - Insight, China's Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"South Korea-based clinical-stage biotech ABL Bio Inc. (KOSDAQ: 298380) has entered into a licensing agreement with GlaxoSmithKline (GSK, NYSE: GSK). The collaboration grants GSK access to ABL Bio's Grabody-B blood-brain barrier (BBB) shuttle platform to develop novel medicines for neurodegenerative diseases. The deal encompasses multiple programs across therapeutic modalities, including antibodies, polynucleotides, and oligonucleotides such as siRNA and ASOs.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=31282\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"ABL Bio and GSK Partner on Neurodegenerative Disease Therapies with Grabody-B Platform\" \/>\n<meta property=\"og:description\" content=\"South Korea-based clinical-stage biotech ABL Bio Inc. (KOSDAQ: 298380) has entered into a licensing agreement with GlaxoSmithKline (GSK, NYSE: GSK). The collaboration grants GSK access to ABL Bio's Grabody-B blood-brain barrier (BBB) shuttle platform to develop novel medicines for neurodegenerative diseases. The deal encompasses multiple programs across therapeutic modalities, including antibodies, polynucleotides, and oligonucleotides such as siRNA and ASOs.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=31282\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China's Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2025-04-07T07:48:58+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2025-04-07T07:48:59+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2025\/04\/0705-png.webp\" \/>\n\t<meta property=\"og:image:width\" content=\"1080\" \/>\n\t<meta property=\"og:image:height\" content=\"608\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"1 minute\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=31282#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=31282\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"ABL Bio and GSK Partner on Neurodegenerative Disease Therapies with Grabody-B Platform\",\"datePublished\":\"2025-04-07T07:48:58+00:00\",\"dateModified\":\"2025-04-07T07:48:59+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=31282\"},\"wordCount\":175,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=31282#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/04\\\/0705-png.webp\",\"keywords\":[\"ABL Bio\",\"GlaxoSmithKline\",\"GSK\",\"KOSDAQ: 298380\",\"NYSE: GSK\"],\"articleSection\":[\"Company\",\"Deals\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=31282#respond\"]}],\"copyrightYear\":\"2025\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=31282\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=31282\",\"name\":\"ABL Bio and GSK Partner on Neurodegenerative Disease Therapies with Grabody-B Platform - Insight, China's Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=31282#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=31282#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/04\\\/0705-png.webp\",\"datePublished\":\"2025-04-07T07:48:58+00:00\",\"dateModified\":\"2025-04-07T07:48:59+00:00\",\"description\":\"South Korea-based clinical-stage biotech ABL Bio Inc. (KOSDAQ: 298380) has entered into a licensing agreement with GlaxoSmithKline (GSK, NYSE: GSK). The collaboration grants GSK access to ABL Bio's Grabody-B blood-brain barrier (BBB) shuttle platform to develop novel medicines for neurodegenerative diseases. The deal encompasses multiple programs across therapeutic modalities, including antibodies, polynucleotides, and oligonucleotides such as siRNA and ASOs.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=31282#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=31282\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=31282#primaryimage\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/04\\\/0705-png.webp\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/04\\\/0705-png.webp\",\"width\":1080,\"height\":608,\"caption\":\"ABL Bio and GSK Partner on Neurodegenerative Disease Therapies with Grabody-B Platform\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=31282#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"ABL Bio and GSK Partner on Neurodegenerative Disease Therapies with Grabody-B Platform\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"ABL Bio and GSK Partner on Neurodegenerative Disease Therapies with Grabody-B Platform - Insight, China's Pharmaceutical Industry","description":"South Korea-based clinical-stage biotech ABL Bio Inc. (KOSDAQ: 298380) has entered into a licensing agreement with GlaxoSmithKline (GSK, NYSE: GSK). The collaboration grants GSK access to ABL Bio's Grabody-B blood-brain barrier (BBB) shuttle platform to develop novel medicines for neurodegenerative diseases. The deal encompasses multiple programs across therapeutic modalities, including antibodies, polynucleotides, and oligonucleotides such as siRNA and ASOs.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=31282","og_locale":"en_US","og_type":"article","og_title":"ABL Bio and GSK Partner on Neurodegenerative Disease Therapies with Grabody-B Platform","og_description":"South Korea-based clinical-stage biotech ABL Bio Inc. (KOSDAQ: 298380) has entered into a licensing agreement with GlaxoSmithKline (GSK, NYSE: GSK). The collaboration grants GSK access to ABL Bio's Grabody-B blood-brain barrier (BBB) shuttle platform to develop novel medicines for neurodegenerative diseases. The deal encompasses multiple programs across therapeutic modalities, including antibodies, polynucleotides, and oligonucleotides such as siRNA and ASOs.","og_url":"https:\/\/flcube.com\/?p=31282","og_site_name":"Insight, China's Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2025-04-07T07:48:58+00:00","article_modified_time":"2025-04-07T07:48:59+00:00","og_image":[{"width":1080,"height":608,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/04\/0705-png.webp","type":"image\/png"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"1 minute"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=31282#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=31282"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"ABL Bio and GSK Partner on Neurodegenerative Disease Therapies with Grabody-B Platform","datePublished":"2025-04-07T07:48:58+00:00","dateModified":"2025-04-07T07:48:59+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=31282"},"wordCount":175,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"image":{"@id":"https:\/\/flcube.com\/?p=31282#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/04\/0705-png.webp","keywords":["ABL Bio","GlaxoSmithKline","GSK","KOSDAQ: 298380","NYSE: GSK"],"articleSection":["Company","Deals"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=31282#respond"]}],"copyrightYear":"2025","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=31282","url":"https:\/\/flcube.com\/?p=31282","name":"ABL Bio and GSK Partner on Neurodegenerative Disease Therapies with Grabody-B Platform - Insight, China's Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/flcube.com\/?p=31282#primaryimage"},"image":{"@id":"https:\/\/flcube.com\/?p=31282#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/04\/0705-png.webp","datePublished":"2025-04-07T07:48:58+00:00","dateModified":"2025-04-07T07:48:59+00:00","description":"South Korea-based clinical-stage biotech ABL Bio Inc. (KOSDAQ: 298380) has entered into a licensing agreement with GlaxoSmithKline (GSK, NYSE: GSK). The collaboration grants GSK access to ABL Bio's Grabody-B blood-brain barrier (BBB) shuttle platform to develop novel medicines for neurodegenerative diseases. The deal encompasses multiple programs across therapeutic modalities, including antibodies, polynucleotides, and oligonucleotides such as siRNA and ASOs.","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=31282#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=31282"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/?p=31282#primaryimage","url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/04\/0705-png.webp","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/04\/0705-png.webp","width":1080,"height":608,"caption":"ABL Bio and GSK Partner on Neurodegenerative Disease Therapies with Grabody-B Platform"},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=31282#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"ABL Bio and GSK Partner on Neurodegenerative Disease Therapies with Grabody-B Platform"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/04\/0705-png.webp","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/31282","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=31282"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/31282\/revisions"}],"predecessor-version":[{"id":31285,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/31282\/revisions\/31285"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/media\/31284"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=31282"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=31282"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=31282"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}